Pharmacotherapy of pandemic and post-pandemic stress-related mental disorders

Janusz Heitzman

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

1/2021
vol. 37

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł przeglądowy

Farmakoterapia pandemicznych i popandemicznych zaburzeń psychicznych związanych ze stresem

Janusz Heitzman

¹

Department of Forensic Psychiatry, Institute of Psychiatry and Neurology

Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 9–32

Data publikacji online: 2021/11/17

Plik artykułu:

- 01R_IPiN_FARM_2021-1D.pdf [0.27 MB]

Pobierz cytowanie

1. Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD Review). The Cochrane Collaboration, The Cochrane Library 2014, Issue 7.

2. Davidson JRT, van der Kolk BA. The Psychopharmacological treatment of Posttraumatic Stress Disorder. W: van der Kolk BA, Mc Farlane AC, Weisaeth L (ed.). Traumatic Stress, The Effects of Overwhelming Experience on Mind Body and Society. New York, Guilford, 1996, s. 511-524.

3. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-844.

4. DSM-5, Diagnostic and statistical manual of mental disorders. 5th ed., Arlington, VA: American Psychiatric Association Publishing; 2013.

5. Friedman MJ. Pharmacologic Management of Posttraumatic Stress Disorder. Primary Psychiatry 2003; 10, 8: 66-73.

6. Gaebel W, Großimlinghaus I, Mucic D, Maercker A, Zielasek J, Kerst A. EPA guidance on eMental health interventions in the treatment of posttraumatic stress disorder (PTSD). European Psychiatry 2017, 41: 140-152.

7. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996, 57 (9): 390-394.

8. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRixiv 2020; DOI: http:// doi.org/10.1101/2020.02.07.937862.

9. Green B. Zespół stresu pourazowego, nowe kierunki farmakoterapii. Med. Prakt. Psychiatria 2015; 4: 9-22.

10. Heitzman J. Wpływ pandemii COVID-19 na zdrowie psychiczne. Psychiatr. Pol. 2020; 54(2): 187-198. DOI: https:// doi.org/10.12740/PP/120373.

11. Heitzman J. Ostre zaburzenia stresowe – możliwości psychoterapeutyczne. W: J. Meder (red.). Zachowania agresywne, przeciwdziałanie, leczenie. Biblioteka Psychiatrii Polskiej, Kraków 2007, 77-92.

12. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B, Seckl JR. Do corticosteroids damage the brain? J Neuroendocrinol. 2006;18: 393-411.

13. Hoge LA, Worthington JJ, Nagurney JT et al. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci. Therapeut. 2012; 18: 21-27.

14. ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization 1992.

15. Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder – a systematic review and meta-analysis. S Afr Med J 2006; 96: 1088-96.

16. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post- -traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology 2011; 15(6): 825-40. DOI:10.1017/ S1461145711001209.

17. Joca SR, Ferreira FR, Guimaraes FS. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic nd nitrergic neurotransmitter systems. Stress 2007; 10: 227-249.

18. Katz C, Stein M, Richardson D i wsp. A review of interventions for treatment-resistant posttraumatic stress disorder. W: Selek DS (ed.). Different views of anxety disorders, Rijeka, InTech Publishing 2011.

19. van der Kolk BA. The drug treatment of post-traumatic stress disorder. Journal of Affective Disorders 1987; 13: 203-213.

20. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz B, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. Journal of Clinical Psychiatry 1994; 55(12): 517-522.

21. Krystal JH. Animal models for post traumatic stress disorder. W: Giller EL (ed.), Biological assessment and treatment of post-traumatic stress disorder. Washington DC: American Psychiatric Press; 1990, s. 3-26.

22. Landowski J. Farmakoterapia stanów lękowych. W: Bijak M, Lasoń W (red.). Neuropsychofarmakologia – dziś i jutro, Instytut Farmakologii PAN, Kraków 2000, 167-190.

23. Lo SC, Ravaldi C, Cabras PL, Faravelli C, Ricca V. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. Neuropsychobiology 2008; 57: 95-115.

24. Meewisse ML, Reitsma JB, de Vries GJ, Gersons BP, Olff M. Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis. Br J Psychiatry. 2007; 191: 387-392.

25. Morganstein JC, Ursano RJ, Fullerton CS, Holloway HC. Pandemics: Health Care Emergencies. W: Ursano RJ, Fullerton SC, Weisaeth L, Raphael B (ed.). Textbook of Disaster Psychiatry, wyd 2. Cambridge: Cambridge University Press 2017, s. 270-283.

26. Moukaddam N, Shah A. Psychiatrists Beware! The Impact of COVID-19 and Pandemics on Mental Health. Psychiatric Times 2020; 37(3): 11-12.

27. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 2004; 9: 23-31.

28. NICE 2018. Guidelines for post-traumatic stress disorder nice guideline (NG116). Retrieved from https://www. nice. org.uk/guidance/ng116.

29. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008; 31: 464-468.

30. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51: 189-192.

31. Raphael B, Wilson J, Meldrum L, McFarlane AC. Acute preventive interventions. W: van der Kolk BA, Mc Farlane AC, Weisaeth L (ed.). Traumatic Stress, The Effects of Overwhelming Experience on Mind Body and Society. New York, Guilford 1996; 463-479.

32. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160: 371-373.

33. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011; 470: 492-497.

34. Ravindran LN, Stein MB. Pharmacotherapy of PTSD: Premises, Principles, and Priorities, Brain Res. 2009, Oct 13; 1293: 24-39.

35. Ritchie EC. Mass violence and early intervention: Best practice Guidelines. Primary Psychiatry 2003; 10 (8): 43-48.

36. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar- -Poli P et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID- 19 pandemic. Lancet Psychiatry 2020; Published online, May 18, 2020; https:// doi.org/10.1016/S2215-0366(20) 30219-4.

37. Roozendaal B, Okuda S, Van der Zee EA, McGaugh JL. Glucocorticoid enhancement of memory requires arousal-induced noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci USA 2006;103:6741-6746.

38. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann NY Acad Sci. 2008; 1141: 105-130.

39. Southwick S M, Krystal J H, Morgan A, Johnson D, Nagy L, Nicolaou A et al. Abnormal noradrenergic function in post- -traumatic stress disorder. Archives of General Psychiatry 1993; 50: 266-274.

40. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007; 20: 923-932.

41. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63: 629-632.

42. Towers S, Afzal S, Bernal G, Bliss N, Brown S. Mass Media and the Contagion of Fear: The Case of Ebola in America. PLoS ONE 2015; http://doi.org/10.1371/journal.pone. 0129179.s001.

43. VA/DoD clinical practice guideline for management of post- -traumatic stress. Washington (DC): Department of Veterans Affairs, Department of Defense; 2010. Available from: http:// www.healthquality.va.gov/ptsd/ptsd_full.pdf.

44. VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction. Washington (DC): Department of Veterans Affairs, Department of Defense; 2017, Mental Health Guidelines. Available from: https://www.healthquality.va.gov/guidelines/mh/ ptsd/index.asp.

45. Vargas MA, Bissette G, Owens MJ, Ehlers CL, Nemeroff CB. Effect of chronic ethanol and benzodiazepine treatment and withdrawal on corticotropin-releasing factor neural systems. An. N. Y. Acad. Sciences 1992, 654: 145-152.

46. Zelena D, Mergl Z, Makara GB. Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons. Brain Res 2005; 1031: 185-193.

Farmakoterapia pandemicznych i popandemicznych zaburzeń psychicznych związanych ze stresem

Janusz Heitzman 1

Janusz Heitzman

¹